CERK and metabolic dysfunction-associated steatotic liver disease: Moreover, oral administration of the sphingosine analog FTY720, which upregulates CerK and is used for the treatment of multiple sclerosis, also ameliorates Alzheimer ́s disease (270) and steatosis in a model of nonalcoholic fatty liver disease (271).